Search Medical Condition
Please enter condition
Please choose location from dropdown

Targu Mures, Romania Clinical Trials

A listing of Targu Mures, Romania clinical trials actively recruiting patients volunteers.

RESULTS

Found (45) clinical trials

A Phase II Study of M2951 in Systemic Lupus Erythematosus (SLE)

M2951 is an investigational drug under evaluation for treatment of autoimmune and inflammatory disorders. The purpose of the study is to assess the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE)

Phase

0.0 miles

Learn More »

Effect of Mepolizumab in Severe Bilateral Nasal Polyps

Nasal polyps (NP) has long been known as chronic inflammatory disease of the nasal mucosa. This disease is characterized by the presence of polyps in the upper nasal cavity, originating from within the ostiomeatal complex. The presence of polyps can cause long-term symptoms such as prominent nasal obstruction, post-nasal drip, ...

Phase

0.0 miles

Learn More »

Study to Evaluate the Effectiveness and Safety of Ocrelizumab in Participants With Early Stage Relapsing Remitting Multiple Sclerosis (RRMS)

This is a prospective, multicenter, open-label, single-arm, phase 3b study which evaluates effectiveness and safety of ocrelizumab in participants with early stage RRMS. The study will consist of an open-label treatment period of 192 weeks and follow-up period of at least 48 weeks.

Phase

0.0 miles

Learn More »

Real-world Use of Carfilzomib Among Multiple Myeloma Patients in Europe

With the recent addition of carfilzomib as a treatment option for multiple myeloma, no data is available yet on how the drug is being used outside of the clinical trial setting. The Primary Objective is to describe carfilzomib utilisation in routine clinical practice, including dosage, administration schedule, regimen, duration of ...

Phase N/A

0.0 miles

Learn More »

Phase IIb Study of Evobrutinib in Subjects With Rheumatoid Arthritis

The purpose of the study is to determine the efficacy, dose response, and safety of evobrutinib in subjects with Rheumatoid Arthritis (RA), and to consider a dose to take forward into Phase III development.

Phase

0.0 miles

Learn More »

A Study to Evaluate Safety and Effects of Sotagliflozin Dose 1 and Dose 2 on Glucose Control in Patients With Type 2 Diabetes Severe Impairment of Kidney Function and Inadequate Blood Sugar Control

The study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment and a visit 4 weeks after completion of the randomized treatment period.

Phase

0.0 miles

Learn More »

Safety and Efficacy Study of Sotagliflozin on Glucose Control in Patients With Type 2 Diabetes Moderate Impairment of Kidney Function and Inadequate Blood Sugar Control

The study duration is up to 60 weeks including 4 weeks prior to randomization, 52 weeks of randomized treatment, and a visit 4 weeks after completion of the randomized treatment period.

Phase

0.0 miles

Learn More »

Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)

Mepolizumab is a humanized monoclonal antibody. In conditions where eosinophilia is considered to play an important part in the pathology, including eosinophilic asthma, HES, and eosinophilic granulomatosis with polyangiitis, a consistent reduction in blood eosinophil counts is observed in association with mepolizumab administration, with concomitant clinical improvement. This is a ...

Phase

0.0 miles

Learn More »

Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure

This is a 24 week, multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the effects of saxagliptin and sitagliptin on cardiac dimensions and function in patients with type 2 diabetes (T2DM) mellitus and heart failure (HF).

Phase

0.0 miles

Learn More »

Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI

The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint ...

Phase

0.0 miles

Learn More »